SCHOTT Pharma Delivers Strong Third Quarter Results and Raises FY 2024 Revenue Guidance

SCHOTT Pharma AG & Co. KGaA has announced robust financial results for Q3 2024. The company reported a 21% year-over-year increase in revenues, reaching EUR 268 million at constant currencies. The EBITDA margin improved to 28.2%, up from 25.1% in Q3 2023.

Significant growth was noted in high-value solutions, which represented 53% of total revenues for the first nine months of FY 2024. The revenue guidance for the entire fiscal year 2024 was raised to 11-13% from the previous 9-11%.

Noteworthy innovations were introduced, including the new 10 ml ready-to-use cartridges for biologics. Additionally, the launch of SCHOTT TOPPAC® Nest 160 aims to enhance sustainability by increasing prefillable polymer syringes per nest, reducing costs and carbon footprint.

Expansion projects are progressing well in Hungary, Serbia, and North Carolina to meet high demand, especially in the Drug Delivery Systems segment. This segment achieved its highest quarterly revenues to date, driven by a 39% increase in prefillable syringes' demand.

SCHOTT Pharma's strong performance in Q3 underscores its well-executed strategy. The company remains focused on innovation and expansion to drive future growth.